Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ventyx Biosciences reports Q1 losses, eyes market growth opportunities

Ventyx Biosciences navigates financial challenges with strong pipeline progress and strategic cash reserves.
Confidence in drug efficacy and proactive commercial planning position the company for market success.
Challenges from market competition and strategic decisions are balanced by growth opportunities and diversification.
Engagement with stakeholders and ongoing program advancements drive optimism for future growth and development.

Ventyx Biosciences progresses in Phase II trials amid commercial challenges

Ventyx Biosciences shows promising progress in Phase II trials for VTX958 and VTX002, with a focus on immune diseases like ulcerative colitis and psoriasis.
Challenges in commercial performance and trial diversity persist, but opportunities lie in upcoming Phase II results and potential expansion into new indications.
The company's financial performance reflects increased R&D investment, while strategic decisions on drug development and market positioning are crucial for future success.
Overall, Ventyx's innovative therapies and perseverance in trials position it for growth, pending successful Phase II outcomes and strategic adaptations.

Ventyx Biosciences reports promising Q1 results, eyes strategic partnerships

Ventyx Biosciences showcased strong performance in key inhibitors and IBD assets, despite facing financial challenges and the need to navigate regulatory complexities. The company's focus on innovation, upcoming trials, and potential partnerships positions them well for future growth and success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc shares sank as much as 20% in pre-market trading on Tuesday after the clinical-stage biopharmaceutical company announced results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely active ulcerative colitis (UC).  Ventyx said 28% of patients on the 60 milligram (mg) dose and 24% of patients on the 30 mg dose achieved the primary endpoint of clinical remission at Week 13 compared to 11% of patients on placebo.

Ventyx Biosciences stock drops as colitis drug trial falls short of expectations

VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and tolerability profile Ventyx to host conference call and webcast today at 4:30 PM ET SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely active ulcerative colitis (UC). “We are very excited to share the positive Phase 2 results for VTX002, which we believe establish VTX002 as a potential best-in-disease oral therapy for UC based on its combined efficacy and safety profile,” said Raju Mohan, Ph.D.

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

Start Time: 16:30 January 1, 0000 5:23 PM ET Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Raju Mohan - Founder and CEO Marty Auster - CFO Bill Sandborn - President and Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Alex Thompson - Stifel Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.

Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript

Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2023

Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference being held on August 9, 2023.

Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Ventyx's shares shot up while insiders were selling. The company is a clinical-stage biotech.

Why Shares of Ventyx Biosciences Rose Monday

Ventyx Biosciences, Inc. has a number of interesting assets in mid-stage trials. The company is founded by a successful serial entrepreneur. Phase 2 data later this year will be pivotal for Ventyx Biosciences prospects.

Ventyx: Critical Proof Of Concept Data Later This Year

Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024 Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

Topline results from the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis are expected in Q4 2023 Topline results from the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis are expected in Q4 2023

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Derek Archila - Wells Fargo Alex Thompson - Stifel Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.

Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Call Transcript

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023

Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

CRISPR Therapeutics

Legend Biotech

Madrigal Pharmaceuticals

Vaxcyte

Revolution Medicines

Western Alliance Bancorporation

Where is the current bull market? All indications would be that it's in biotech!

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

The stock price of Ventyx Biosciences Inc (NASDAQ: VTYX) fell by over 4% intraday today. This is why.

Ventyx Biosciences Stock Flals Over 4%: Details

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q4 2022 Earnings Conference Call March 24, 2023 4:30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Jeff Jones - Oppenheimer Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright & Co Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Fourth Quarter and Full Year 2022 Earnings Conference Call.

Ventyx Biosciences, Inc. (VTYX) Q4 2022 Earnings Call Transcript

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on March 23, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver.

Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Ventyx Biosciences, Inc. (VTYX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 26.67% Upside in Ventyx Biosciences, Inc. (VTYX): Can the Stock Really Move This High?

Ventyx Biosciences, Inc. (VTYX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's Why

Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great Choice

The consensus price target hints at a 39% upside potential for Ventyx Biosciences, Inc. (VTYX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a Bet

Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn's disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023

News for Ventyx Biosciences Stock (VTYX)